Cinacalcet as adjunctive therapy for hereditary 1,25-dihydroxyvitamin D–resistant rickets

Authors

  • Tarak Srivastava,

    1. Section of Nephrology, Bone and Mineral Disorder Clinic, Children's Mercy Hospitals and Clinics, University of Missouri at Kansas City, Kansas City, MO, USA
    Search for more papers by this author
  • Uri S Alon

    Corresponding author
    1. Section of Nephrology, Bone and Mineral Disorder Clinic, Children's Mercy Hospitals and Clinics, University of Missouri at Kansas City, Kansas City, MO, USA
    • Section of Nephrology, Children's Mercy Hospital, 2401 Gillham Road, Kansas City, MO 64108, USA.
    Search for more papers by this author

Abstract

Secondary hyperparathyroidism from inadequate calcium absorption in the gut, is the underlying pathophysiology for rachitic changes in hereditary vitamin D–resistant rickets (HVDRR). We describe a novel use of Cinacalcet to treat a child with HVDRR in whom conventional modes of therapy had to be discontinued. Cinacalcet therapy with high-dose oral calcium effectively normalized the metabolic abnormalities and bone condition. The relative ease of administration of the calcimimetic as a once- or twice-daily oral preparation, compared with traditional intravenous calcium administration, should encourage its move to the frontline of treatment of the disorder. © 2013 American Society for Bone and Mineral Research.

Ancillary